06 Dec 2022
Bactobio Ltd, one of Granatus successful portfolio companies, has closed an oversubscribed £6 million bridge financing round.
The announced funds will be used to advance Bactobio’s pioneering discovery pipeline of the next generation of antimicrobial solutions (antibiotics).
Bactobio is a biotechnology company using breakthrough technologies in synthetic biology, next-generation sequencing and machine learning to cultivate the 99% of microbes in nature which have previously been unculturable.
Granatus is one of the first investors in the company.
More information is here >>